Facts & Figures

Actelion - A global biopharmaceutical leader 


Actelion Ltd
Actelion Pharmaceuticals Ltd 

Corporate structure

Actelion Ltd is a public company and listed on the Swiss stock exchange (SIX)


17 December 1997

Founding team

Jean-Paul Clozel, Walter Fischli, Thomas Widmann, Martine Clozel, Andre Mueller

Head office

Actelion Ltd & Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil, Switzerland
phone + 41 61 565 65 65
fax     + 41 61 565 65 00

Global presence

Actelion has subsidiaries with marketing and sales in more than 30 countries, covering all key pharmaceutical markets worldwide.

Our Specialty

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.